WASHINGTON (AP) — Federal regulators responsible for the safety of the U.S. drug supply are still struggling to get back to where they were in 2019, before the COVID-19 pandemic upended factory ...

As COVID-19 swept across the globe in early 2020, the Food and Drug Administration (FDA) pulled most of its safety inspectors from the field, creating a massive backlog of uninspected pharmaceutical ...

While the FDA’s inspection figures for drug manufacturing facilities have yet to fully recover from the COVID-19 pandemic, sweeping staff cuts have raised questions about how the agency plans to ...

Nearly 2,000 drug plants have still not been inspected since the COVID-19 pandemic halted global factory checks, an investigation by The Associated Press (AP) found. The AP reported on Thursday that ...

WASHINGTON — As COVID-19 swept across the globe in early 2020, the Food and Drug Administration pulled most of its safety inspectors from the field, creating a massive backlog of uninspected ...

The FDA continues to face significant staffing shortages in its drug inspection workforce, according to a new report from the Government Accountability Office. Despite some progress in resuming ...

This article originally appeared on ProPublica. ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox.

The FDA is preparing to scale back on routine drug inspections following widespread layoffs in support staff, multiple officials told CBS News. Around 170 employees were cut from the FDA’s Office of ...